Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining an expanding group of drugmakers pulling back from the European ...

Amid a steady advance of kidney-focused label expansions, Novartis’ Fabhalta is slowing its roll in a key potential autoimmune niche.  | Amid a steady advance of kidney-focused label expansions, ...

The evolution of AI in clinical development is increasingly a story of action, not only insight. Predictive models helped ...

Eli Lilly is betting on a pediatric expansion to give it’s IL-23p19 inhibitor Omvoh an edge in the fiercely competitive ...

Legendary actress Viola Davis’s newest role sees her getting real about shingles as a GSK spokesperson, reminding others that ...

Central to the new report (PDF) are the JEC Democrats' findings that Trump increased his stock holdings in the pharmaceutical ...

Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...

Sanofi is gearing up for another major sports sponsorship in its home country, this time with the 2027 Tour de France. | The ...

In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new ...

Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...

Roche extended its China shopping spree with a $1 billion-plus obesity deal. | Roche extended its China shopping spree with a ...

Meridian Medical Technologies—the global health security subsidiary of CDMO Kindeva—just secured a major contract, worth up to a potential $226 million, with the DoD's Defense Logistics Agency to ...